Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident - Seeking Alpha

Boston Scientific (BSX) is facing a Q3 earnings miss due to recent product recalls, a cybersecurity incident, and repeated guidance cuts, according to an analyst report. The medical device company remains a 'hold' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments.

Strategic Shift

Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028. Despite these efforts, near-term visibility remains clouded by recent challenges.

Mixed Outlook

Despite improved margins and a strong innovation pipeline, BSX's risk/reward profile is not compelling enough for a buy at current valuation. The company, headquartered in Massachusetts and founded in 1979, operates primarily in Cardiovascular and MedSurg segments, with the former representing about 2/3rd of their Q2 2026 revenue.